- Home
- Asia Pacific Pharmacogenetic Testing In Psychiatry Depression Market
Asia-Pacific Pharmacogenetic Testing in Psychiatry Depression Market - Industry Trends and Forecast to 2028
- Published Date: September, 2022 | Report ID: CLS-99 | No of pages: 180 | Format:
Asia-Pacific pharmacogenetic testing in psychiatry/depression market is projected to register a CAGR of 10.6% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028
Market Segmentation:
Asia-Pacific Pharmacogenetic Testing in Psychiatry/Depression Market, By Type (Whole Genome Sequencing and Array-Based Tests), Genes (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT and Others), Drug Type (Prescription Drugs, Over-the-Counter Medications, Recreational Drugs and Vitamins/Nutraceuticals), Sample Type (Saliva and Blood), Application (Drug Development and Clinical Practice), End User (Pharmaceutical & Biotechnology Companies, Research Centers and Academic Institutes, Healthcare Providers and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Direct-To-Consumer Services and Mail-Order Pharmacies), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2028
Some of the major factors contributing to the growth of the Asia-Pacific pharmacogenetic testing in psychiatry/depression market are:
Rising population suffering from major depressive disorders
Growing demand of personalized medicine
Market Players:
The key market players for Asia-Pacific pharmacogenetic testing in psychiatry/depression market are listed below:
BiogeniQ Inc.
GenXys
Genomind, Inc.
Myriad Genetics, Inc.
AltheaDx
STADA Arzneimittel AG
Sonic Healthcare
ONEOME
Thermo Fisher Scientific Inc.
Millennium Health
Coriell Life Sciences
Healthspek
Color
GENELEX
OmeCare
AB-Biotics, S.A.
Luminex Corporation
Illumina, Inc.
PerkinElmer Inc.
HudsonAlpha Health Alliance (a division of HudsonAlpha)
Dynamic DNA Laboratories
cnsdose,
myDNA Life Australia Pty Ltd.
R-Biopharm AG
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.10 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 REGULATIONS: ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
5.1 UNITED STATES
5.1.1 ROLE OF FDA
5.1.2 ROLE OF CDC AND HCFA
5.2 EUROPEAN UNION
5.3 FRANCE
5.4 AUSTRALIA
5.5 SOUTH KOREA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING NUMBER OF POPULATION SUFFERING FROM DEPRESSIVE DISORDER
6.1.2 INITIATIVES TAKEN BY MANUFACTURERS
6.1.3 GROWING BIOTECHNOLOGY SECTOR ALONG WITH RISING HEALTHCARE EXPENDITURE
6.1.4 INCREASING INTEREST FOR PERSONALIZED AND PRECISION MEDICATION
6.1.5 GROWING MEDICAL TOURISM
6.2 RESTRAINTS
6.2.1 LACK OF STRONG CLINICAL EVIDENCE
6.2.2 HIGH COST
6.2.3 LACK OF REIMBURSEMENT
6.3 OPPORTUNITIES
6.3.1 TECHNOLOGICAL ADVANCEMENTS
6.3.2 EMERGENCE OF NEW PLAYERS
6.3.3 UNTAPPED MARKET
6.4 CHALLENGES
6.4.1 STRINGENT GOVERNMENT REGULATION
6.4.2 SHORTAGE OF SKILLED PERSONNEL
7 COVID-19 IMPACT ON ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY
7.4 KEY INITIATIVES BY MARKET PLAYER DURING COVID 19
7.5 CONCLUSION:
8 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE
8.1 OVERVIEW
8.2 WHOLE GENOME SEQUENCING
8.3 ARRAY-BASED TESTS
9 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES
9.1 OVERVIEW
9.2 CYP2C19
9.3 CYP2C9 AND VKORC1
9.4 CYP2D6
9.5 HLA-B
9.6 HTR2A/C
9.7 HLA-A
9.8 CYP3A4
9.9 SLC6A4
9.10 MTHFR
9.11 COMT
9.12 OTHERS
10 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE
10.1 OVERVIEW
10.2 PRESCRIPTION DRUGS
10.3 OVER-THE-COUNTER MEDICATIONS
10.4 RECREATIONAL DRUGS
10.5 VITAMINS/NUTRACEUTICALS
11 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE
11.1 OVERVIEW
11.2 SALIVA
11.3 BLOOD
12 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 DRUG DEVELOPMENT
12.3 CLINICAL PRACTICE
13 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER
13.1 OVERVIEW
13.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
13.3 HEALTHCARE PROVIDERS
13.4 RESEARCH CENTERS AND ACADEMIC INSTITUES
13.5 OTHERS
14 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 RETAIL PHARMACIES
14.3 HOSPITAL PHARMACIES
14.4 MAIL-ORDER PHARMACIES
14.5 DIRECT-TO-CUSTOMER SERVICES
15 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GEOGRAPHY
15.1 ASIA-PACIFIC
15.1.1 JAPAN
15.1.2 CHINA
15.1.3 SOUTH KOREA
15.1.4 INDIA
15.1.5 AUSTRALIA
15.1.6 SINGAPORE
15.1.7 THAILAND
15.1.8 MALAYSIA
15.1.9 INDONESIA
15.1.10 PHILIPPINES
15.1.11 REST OF ASIA-PACIFIC
16 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 MYRIAD GENETICS, INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 THERMO FISHER SCIENTIFIC INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 STADA ARZNEIMITTEL AG
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 SONIC HEALTHCARE
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 ILLUMINA, INC.
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 AB-BIOTICS, S.A.
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENTS
18.7 ALTHEADX
18.7.1 COMPANY SNAPSHOT
18.7.2 PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENT
18.8 BIOGENIQ INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 COLOR
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENTS
18.10 CNSDOSE
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 CORIELL LIFE SCIENCES
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENTS
18.12 DYNAMIC DNA LABORATORIES
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENTS
18.13 GENELEX
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
18.14 GENOMIND, INC.
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENTS
18.15 GENXYS
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENTS
18.16 HEALTHSPEK
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENT
18.17 HUDSONALPHA HEALTH ALLIANCE (A DIVISION OF HUDSONALPHA)
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENT
18.18 LUMINEX CORPORATION
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENTS
18.19 MILLENNIUM HEALTH
18.19.1 COMPANY SNAPSHOT
18.19.2 PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENTS
18.20 MYDNA LIFE AUSTRALIA PTY LTD.
18.20.1 COMPANY SNAPSHOT
18.20.2 PRODUCT PORTFOLIO
18.20.3 RECENT DEVELOPMENT
18.21 ONEOME
18.21.1 COMPANY SNAPSHOT
18.21.2 PRODUCT PORTFOLIO
18.21.3 RECENT DEVELOPMENTS
18.22 OMECARE
18.22.1 COMPANY SNAPSHOT
18.22.2 PRODUCT PORTFOLIO
18.22.3 RECENT DEVELOPMENT
18.23 PERKINELMER INC.
18.23.1 COMPANY SNAPSHOT
18.23.2 REVENUE ANALYSIS
18.23.3 PRODUCT PORTFOLIO
18.23.4 RECENT DEVELOPMENTS
18.24 R-BIOPHARM AG
18.24.1 COMPANY SNAPSHOT
18.24.2 PRODUCT PORTFOLIO
18.24.3 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
Segmentation
Short Description
Asia-Pacific Pharmacogenetic Testing in Psychiatry/Depression Market, By Type (Whole Genome Sequencing and Array-Based Tests), Genes (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT and Others), Drug Type (Prescription Drugs, Over-the-Counter Medications, Recreational Drugs and Vitamins/Nutraceuticals), Sample Type (Saliva and Blood), Application (Drug Development and Clinical Practice), End User (Pharmaceutical & Biotechnology Companies, Research Centers and Academic Institutes, Healthcare Providers and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Direct-to-Consumer Services and Mail-Order Pharmacies), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2028
Market Definition:
Pharmacogenetic test is a drug gene test which is used to determine the interaction between the drug and the genetic make-up of the individual. These tests aid the medical professionals to choose the best medicine for the person who is undertaking the drug because it is observed that different people react differently to drugs based on the expression of genes induced by the drugs.
Market Segmentation:
The pharmacogenetic testing in psychiatry/depression market is categorized into seven notable segments which are based on the type, genes, drug type, sample, application, end user and distribution channel.
On the basis of type, the pharmacogenetic testing in psychiatry/depression market is segmented into whole genome sequencing and array-based tests
On the basis of genes, the pharmacogenetic testing in psychiatry/depression market is segmented into CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT and others
On the basis of drug type, the pharmacogenetic testing in psychiatry/depression market is segmented into prescription drugs, over-the-counter medications, recreational drugs and vitamins/nutraceuticals
On the basis of sample, the pharmacogenetic testing in psychiatry/depression market is segmented into saliva and blood
On the basis of application, the pharmacogenetic testing in psychiatry/depression market is segmented into drug development and clinical practice
On the basis of end user, the pharmacogenetic testing in psychiatry/depression market is segmented into pharmaceutical & biotechnology companies, research centers and academic institutes, healthcare providers and others
On the basis of distribution channel, the pharmacogenetic testing in psychiatry/depression market is segmented into hospital pharmacies, retail pharmacies, direct-to-consumer services and mail-order pharmacies
Market Players
The key market players for Asia-Pacific pharmacogenetic testing in psychiatry/depression market are listed below:
BiogeniQ Inc.
GenXys
Genomind, Inc.
Myriad Genetics, Inc.
AltheaDx
STADA Arzneimittel AG
Sonic Healthcare
ONEOME
Thermo Fisher Scientific Inc.
Millennium Health
Coriell Life Sciences
Healthspek
Color
GENELEX
OmeCare
AB-Biotics, S.A.
Luminex Corporation
Illumina, Inc.
PerkinElmer Inc.
HudsonAlpha Health Alliance (a division of HudsonAlpha)
Dynamic DNA Laboratories
cnsdose,
myDNA Life Australia Pty Ltd.
R-Biopharm AG
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.